Skip to main content
Premium Trial:

Request an Annual Quote

AstraZeneca Expands Licensing Deal With InforSense for KDE Software

NEW YORK, Dec. 15 (GenomeWeb News) - InforSense and AstraZeneca have extended a previously existing licensing agreement, the firms said today.

 

As part of a new multi-year global licensing deal, scientists at AstraZeneca R&D sites will use InforSense's workflow-based integrative analytics software, InforSense KDE, in their core drug-discovery programs. 

 

AstraZeneca has used InforSense technology since 2001, the companies said.  The new deal expands access to InforSense KDE across AstraZeneca's R&D organization for integrative biology, chemistry, and text-mining applications. 

 

Financial terms of the agreement were not disclosed.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.